Circulating Bcl-2 concentrations and septic patient mortality

Enferm Infecc Microbiol Clin (Engl Ed). 2021 Aug-Sep;39(7):330-334. doi: 10.1016/j.eimce.2020.06.017.


Introduction: There are not data on blood B-cell lymphoma 2 (Bcl-2) concentrations (one of the antiapoptotic molecules of the Bcl-2 family in the intrinsic apoptosis pathway) in septic patients. Therefore, this study was carried with the aims to explore whether blood Bcl-2 concentrations at diagnosis of sepsis are different in survivor and non-survivor septic patients, are associated with mortality, and are useful for the mortality prediction.

Methods: Intensive Care Units from 3 Spanish hospitals participated in this observational and prospective study with septic patients and serum Bcl-2 concentrations at diagnosis of sepsis were determined. Mortality at 30 days was as outcome variable.

Results: We found that 30-day non-surviving patients (n=81) showed lower serum Bcl-2 levels (p=0.003) than surviving patients (n=140). We found that serum concentrations of Bcl-2<4.4ng/mL were associated with mortality (OR=3.228; 95% CI=1.406-7.415; p=0.006) in the multiple logistic regression analysis, and that showed an area under the curve for mortality prediction of 62% (95% CI=55-68%; p=0.003).

Conclusions: In our study appears novel findings such as higher blood Bcl-2 concentrations in survivor than in non-survivor septic patients, the association between low blood Bcl-2 concentrations and mortality of septic patients, and the ability of blood Bcl-2 concentrations for the prediction of septic patient mortality.

Keywords: Apoptosis; Bcl2; Mortalidad; Mortality; Outcome; Resultado; Sepsis.

Publication types

  • Observational Study

MeSH terms

  • Humans
  • Intensive Care Units
  • Prospective Studies
  • Sepsis*
  • Survivors